Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 11;15(4):1171.
doi: 10.3390/cancers15041171.

CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets

John Maher  1   2   3 , David M Davies  3
Affiliations
Review

CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets

John Maher et al. Cancers (Basel). .

Abstract

Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data generated in clinical trials in which patients with solid tumours that expressed any of 30 discrete targets were treated with CAR-based immunotherapy. That exercise confirms that efficacy of this approach falls well behind that seen in haematological malignancies, while significant toxic events have also been reported. Here, we consider approximately 60 additional candidates for which such clinical data are not available yet, but where pre-clinical data have provided support for their advancement to clinical evaluation as CAR target antigens.

Keywords: NK cell; T-cell; chimeric antigen receptor; solid tumour; target; toxicity.

PubMed Disclaimer

Conflict of interest statement

J.M. is founding scientist, Chief Scientific Officer and shareholder of Leucid Bio. D.M.D. is an employee and shareholder of Leucid Bio.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Halim L., Maher J. CAR T-cell immunotherapy of B-cell malignancy: The story so far. Ther. Adv. Vaccines Immunother. 2020;8:2515135520927164. doi: 10.1177/2515135520927164. - DOI - PMC - PubMed
    1. Van de Donk N., Usmani S.Z., Yong K. CAR T-cell therapy for multiple myeloma: State of the art and prospects. Lancet Haematol. 2021;8:e446–e461. doi: 10.1016/S2352-3026(21)00057-0. - DOI - PubMed
    1. Maher J., Davies D.M. CAR based immunotherapy of solid tumours – a clinically based review of target antigens. Biology. 2023;12:287. doi: 10.3390/biology12020287. - DOI - PMC - PubMed
    1. Hwang M.S., Miller M.S., Thirawatananond P., Douglass J., Wright K.M., Hsiue E.H., Mog B.J., Aytenfisu T.Y., Murphy M.B., Aitana Azurmendi P., et al. Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. Nat. Commun. 2021;12:5271. doi: 10.1038/s41467-021-25605-4. - DOI - PMC - PubMed
    1. Arman I., Haus-Cohen M., Reiter Y. The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy. Cells. 2022;12:27. doi: 10.3390/cells12010027. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources